# ATHENA OS Phase 1D — Final Assessment

## Bottom line
**Harsh implemented-build quality grade: approximately 9.82 / 10.**

This is a quality judgment of the implemented research/product artifact, not a guarantee of MIT THINK selection. The score remains below 9.9 because no amount of retrospective reanalysis can substitute for a genuinely new prospective ATHENA cohort or fully independent external replication.

## Why v2.4.0 moved upward
- The primary NRCD result now has both athlete-cluster bootstrap uncertainty and an equal-athlete paired sign-flip randomization diagnostic.
- The app exposes predefined subgroup error, interval coverage, and Evidence Gate coverage, including weak groups.
- PMData now has exact participant-level randomization uncertainty, alternate chronological split sensitivity, and a scrambled-target negative control.
- An automated Evidence Integrity release gate verifies raw-data hashes, generated results, claim direction, negative controls, and claim boundaries.
- The claim ledger is visible in the product, so reviewers can trace headline statements to exact artifacts.

## Primary real-world performance evidence
- 11,745 held-out 2025 predictions
- personalized baseline: **4.023% MAPE**
- ATHENA: **3.936% MAPE**
- relative improvement: **2.16%**
- rolling-origin folds improved: **3/3**
- athlete-cluster bootstrap 95% interval excludes zero
- equal-athlete 20,000-sign-flip one-sided p **< 0.00005**
- deeper-history groups show larger improvements; subgroup calibration gaps are surfaced rather than hidden

## Secondary real-world wellness evidence
- 341 later-period PMData predictions
- persistence: **1.029 MAE**
- ATHENA: **0.945 MAE**
- relative improvement: **8.22%**
- alternate chronological splits preserve improvement direction
- LOPO beats persistence for **12/16** participants
- participant-cluster interval crosses zero
- exact participant-level two-sided sign-flip **p ≈ 0.207**

The last two points are intentionally retained as limitations.

## Feasibility
The app remains static/local-first with no required API key, backend, paid model service, or GPU. Pallas remains API-key free. Both research pipelines are reproducible on CPU, and the evidence verifier runs automatically after artifact generation.

## Why this is still not 9.9
1. No genuine prospective ATHENA-specific outcome cohort yet.
2. PMData is small; its participant-level uncertainty is not definitive.
3. REST/PhysioNet are identified as legitimate real-world extension domains, but they are not falsely labeled as ATHENA reanalyses in this release.
4. Primary performance improvement is real but modest.
5. Some subgroup prediction-interval coverage is below the 80% nominal target.
6. Novelty remains a claim that must be freshly defended against the literature at submission time.

## Highest-value path from ~9.82 toward ~9.9
- run the already-built locked prospective mode on genuinely future observations under appropriate supervision/consent;
- replicate the wellness protocol in a larger independent cohort;
- have an independent person reproduce the repository from raw data;
- run a small usability/comprehension study;
- perform the final publication-level novelty audit immediately before the THINK proposal is frozen.

Do not chase the remaining gap with random transformers, forced quantum branding, a fake medical predictor, or extra screens. The ceiling is now new evidence, not feature count.
